Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate

Mar 26, 2015

LAS VEGAS, March 26, 2015 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) announced today the debut of a new mobile app designed to serve as a feature-rich resource for patients of its *Gel-One*® Hyaluronate product.



For those experiencing knee pain, the *Gel-One* Patient App from Zimmer provides valuable information about the causes of knee pain and helps them understand more about the potential of *Gel-One* Hyaluronate as a safe and simple non-surgical treatment option. For those who have had a *Gel-One* Hyaluronate injection or are looking to get one, the app offers a number of features, including educational resources on *Gel-One* Hyaluronate, a location-based surgeon finder, and a pain tracker that enables patients to record their pain level on a daily basis.

"Just like the *Gel-One* product itself, this app is about empowering patients and helping them learn more about the outstanding non-surgical options at their disposal," said Seth Middleton, Director, Sales and Marketing, Early Intervention. "By providing a simple user interface and the ability to track pain and activity levels, the new *Gel-One* Patient App can give patients a streamlined and centralized experience - and help them better understand how *Gel-One* Hyaluronate works."

The *Gel-One* Patient App is out today and available in both the Apple iTunes App Store and the Google Play Store. For more information or to download, visit geloneapp.com.

Gel-One® is a registered trademark of Seikagaku Corporation.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in

more than 100 countries. Zimmer's 2014 sales were approximately $4.7 billion. The Company is supported by the efforts of more than 9,000 employees worldwide. More information about Zimmer is available at *www.zimmer.com*.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of Zimmer's management and are subject to significant risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to: future test results or patient experiences being inconsistent with test findings to date; actions of regulatory bodies or other governmental authorities; changes in laws and regulations; competitive developments; and other risks and uncertainties described in Zimmer's periodic reports filed with the U.S. Securities and Exchange Commission. Zimmer disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in Zimmer's periodic reports. Readers of this communication are cautioned not to place undue reliance on these forward-looking statements, since, while management believes the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate.

Logo - http://photos.prnewswire.com/prnh/20131216/MM33947LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/zimmer-launches-new-patient-education-and-engagement-mobile-app-for-gel-one-hyaluronate-300056444.html

SOURCE Zimmer Holdings, Inc.

News Provided by Acquire Media